Mania News and Research

RSS

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Schizophrenia and bipolar disorder affect 3% to 4% of the world's population, or about 222 million adults worldwide. In the United States, bipolar disorder affects about 5.7 million adult Americans 18 and older. Bipolar disorder, or manic depression, is a serious brain disorder that causes extreme shifts in mood, energy and functioning. People with the disorder experience episodes of mania and depression that can last from days to months. These symptoms usually begin in late adolescence, but can begin in early childhood or as late as a person's 40s or 50s. There is a strong genetic component related to bipolar disorder.

28 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Anxiety in school is seasonal and age dependent: Pediatric psychiatrists

With summer fading, anxiety is on the rise for some students anticipating the return of school. But it isn't just the first days of classes that can provoke angst -- anxiety in school is seasonal and age dependent, say pediatric psychiatrists.

2 Sep 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania.

30 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Students with ADHD less likely to finish high school graduation: Study

Teens with attention-deficit/hyperactivity disorder - the most common childhood psychiatric condition in the United States - are less likely to finish high school on time than students with other mental-health disorders that often are considered more serious, a large national study by researchers at the UC Davis School of Medicine has found. The study found that nearly one third of students with ADHD, twice the proportion as students with no psychiatric disorder, either drop out or delay high school graduation.

28 Jul 2010

N.J. Gov. still undecided on whether to join lawsuit against overhaul while health care costs roil Mass. Governor's race

The Philadelphia Inquirer: N.J. "Gov. Christie says he has not decided whether to sign on to a 20-state lawsuit challenging the constitutionality of the health-care law signed in March by President Obama. That makes New Jersey one of seven Republican-led states that have not joined the largely partisan fight. Interest groups on both sides of the debate are lobbying the governor, but some of his advisers say he should not join the suit.

29 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Hospitals shift business plans for waning economy, changing government policies

A sluggish economy, changing government regulation and court cases have prompted new business strategies at hospitals, according to news reports.

22 Jun 2010

Hypertension linked to severity of bipolar disorders

Nearly half of patients hospitalized with bipolar disorder may suffer from hypertension, and the younger a person is diagnosed with the psychiatric condition the more likely they are to develop high blood pressure, according to a recent Michigan State University study.

11 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Diagnostic change not enough to help children diagnosed with bipolar disorder

Shifting children from the controversial diagnosis of bipolar disorder to one that more accurately reflects their symptoms will not by itself decrease the rate of psychopharmacologic treatment and is not enough to help troubled children flourish, according to a commentary in the May 20, 2010 issue of the New England Journal of Medicine by researchers at The Hastings Center, a bioethics research institute, and a physician-researcher at Stony Brook University School of Medicine.

19 May 2010

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

A new study yields important new evidence that the use of atypical antipsychotics among the elderly for off-label purposes is associated with increased risk of developing diabetes.

14 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

Mania News and Research

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Anxiety in school is seasonal and age dependent: Pediatric psychiatrists

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Students with ADHD less likely to finish high school graduation: Study

N.J. Gov. still undecided on whether to join lawsuit against overhaul while health care costs roil Mass. Governor's race

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Hospitals shift business plans for waning economy, changing government policies

Hypertension linked to severity of bipolar disorders

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Diagnostic change not enough to help children diagnosed with bipolar disorder

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

New classification of depressive subtypes of depression proposed

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News